我是 LongbridgeAI，我可以總結文章信息。羅森律師事務所呼籲 Atara Biotherapeutics, Inc.（納斯達克代碼：ATRA）的股東，如果損失超過 10 萬美元，請加入集體訴訟。訴訟指控 Atara 在其業務運營方面誤導投資者，特別是在其 tabelecleucel 生物製品許可證申請的製造問題和監管前景方面。股東可以在 2026 年 5 月 22 日之前提交動議，申請擔任主要原告。該事務所按成功收費的方式運營，意味着只有在獲得賠償時才收取費用
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom.”
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the U.S. Food and Drug Administration (“FDA”) would approve the tabelecleucel Biologics License Application (“BLA”); (2) accordingly, tabelecleucel’s regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara’s business and financial condition; and (5) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Atara Biotherapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by May 22, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260522981710/en/